Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy

Sponsor
Bayer
Study ID
NCT01771081
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ranibizumab (or other DME treatment) — DRUG
    Patients with DME having started treatment with an approved anti-VEGF therapy at or after 01 October 2012 and then continuing with this or any kind or no treatment

Study Details

POLARIS : A non-interventional study in patients with diabetic macular edema (DME) with central involvement to assess the effectiveness of existing anti-vascular endothelial growth factor (anti-VEGF) treatment regimens.

Key Dates

First listed
Jan 18, 2013
Start date
Apr 30, 2013
Status verified
Oct 2015
Primary completion
Jan 31, 2015
Completion
Apr 30, 2015

Study Design

Enrollment
911 participants (actual)

Arms

  • Arm: Group1

Primary Outcome Measure

Changes in visual acuity, assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) or SNELLEN [ Time Frame: Baseline, after 12 months ]

Related Studies